View QT Drugs Lists

  View Southwestern
  U.S. Hispanic
  Herbal Remedies

  Education for
  Professionals

  Women's Health  
 
 
C Path
Arizona Health Sciences Center
Center for Education & Research on Therapeutics
     
©2002 Arizona CERT
Google


Search WWW
Search azcert.org

    

 

ArizonaCERT Publications

Publications & Journal Articles.


ArizonaCERT Publications

2006

Abarca J, Colon LR, Wang VS, Malone DC, Murphy JE, Armstrong EP. Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies. Journal of Managed Care Pharmacy 2006;12(5):383-389.

Abarca J, Malone DC, Skrepnek G, Rehfeld R, Murphy JE, Grizzle AJ, Armstrong EP,  Woosley RL. Community pharmacy managers’ perception of computerized drug-drug interaction alerts. J Am Pharm Assoc 2006;46(2):148-153.

Brown M, Frost R, Ko Y, Woosley RL. Diagramming patients’ views of root causes of adverse drug events in ambulatory care: An online tool for planning education and research. Patient Education and Counseling. 2006;62(3):305-315. Epub 2006 Jul 31.

Indik JH, Pearson EC, Fried K, Woosley RL. Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm 2006; 3(9):1003-1007.

Johnson L, Strich H, Taylor A, Timmermann B, Malone D, Teufel-Shone N, Drummond R, Woosley R, Pereira E, Martinez A. Use of herbal remedies by diabetic Hispanic women in the southwestern United States. Phytotherapy Research. 2006;20(4):250-255.

Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and non-torsadogenic drugs. J Pharmacol Exp Ther 2006. 316(3):1098-1106. Epub 2005 Nov 8.

Ko Y, Brown M, Frost R, Woosley RL. Development of a prescription medication information webliography for consumers.   J Gen Intern Med. 2006 Dec;21(12):1313-6. Epub 2006 Sep 25

Murphy JE, Malone DC, Skrepnek GH, Armstrong EP, Abarca J, Grizzle A, Rehfeld R, Woosley RL. The role of technicians in the management of computerized drug-drug interaction alerts in community pharmacies. Journal of Pharmacy Technology 2006;22:155-160.

Perkins NA, Murphy JE, Malone DC, Armstrong EP. Performance of drug-drug interaction software for personal digital assistants. Ann Pharmacother; 2006;40(5):850-855. Epub 2006 Apr 18.

Skrepnek GH, Armstrong EP, Malone DC, Abarca J, Murphy JE, Grizzle AJ, Rehfeld R, Woosley RL. Workload and availability of technology in metropolitan community pharmacies. J Am Pharm Assoc 2006;46(2):154-160.


2005

Malone DC, Hutchins DS, Haupert H, Hansten P, Duncan B, Van Bergen RC, Solomon SL, Lipton RB. Assessment of potential drug-drug interactions with a prescription claims database. Am J. Health-System Pharmacy 2005;62(19):1983-1991.

Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiology and Drug Safety 2005;14(11):747-753.

Skrepnek GH, Abarca J, Malone DC, Armstrong EP, Shirazi FM, Woosley RL. Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costs. The Annals of Pharmacotherapy 2005;39(11):1785-1791. 


2004

Curtis LH, Law AW, Anstrom KJ, Schulman KA. Insurance effect on prescription drug expenditures among the elderly: findings from the 1997 medical expenditure panel survey. Medical Care. 2004;42(5):439-446.

Curtis LH, Ostbye T, Sendersky V, Hutchison S, Dans PE, Wright A, Woosley RL, Schulman KA. Inappropriate prescribing for elderly Americans in a large outpatient population. Arch Intern Med. 2004;164(15):1621-1625.

Malone DC, Abarca J, Hansten PD, Grizzle AJ, Armstrong EP, Van Bergen RC, Duncan-Edgar BS, Solomon SL, Lipton RB. Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. J Am Pharm Assoc (Wash DC ) 2004; 44(2):142-151.

Murphy JE, Forrey RA, Desiraju U. Community pharmacists' responses to drug-drug interaction alerts. Am J Health-Syst Pharm. 2004;61(14):1484-1487

Woosley RL. Discovering adverse reactions: why does it take so long? Clinical Pharmacology and Therapeutics. 2004;76(4):287-289.


2003

Kornick CA, Kilborn MJ, Santiago-Palma J, Keefe DL, Katchman AN, Schulman G, Ebert SN, Woosley RL, Payne R, Manfredi PL. QTc interval prolongation associated with intravenous methadone. Pain. 2003;105(3):499-506.

Liu X, Katchman A, Whitfield BH, Wan G, Janowski EM, Woosley RL, Ebert SN. In vivo androgen treatment shortens the QT interval and increases the destinies of IKr and of IK1 repolarizing potassium currents in orchiectomized male rabbits. Cardiovascular Research 2003;57(1):28-36.


2002

Flockhart DA, Yasuda SU, Pezzullo JC, Knollmann BC. Teaching rational prescribing: a new clinical pharmacology curriculum for medical schools. Nauyn Schmiedebergs Arch Pharmacol 2002;366:33-43

Katchman AN, McGroary KA, Kilborn MJ, Kornick CA, Manfredi PL, Woosley RL, Ebert SN, Influence of Opioid Agonists on Cardiac Human Ether-a-go-go related Gene K+ Currents. J Pharmacol Exp Ther 2002;303:688-694

Katchman AN, Woosley RL, Ebert SN. Comparative evaluation of opioid agonists on HERG K+ current. World Congress of Pharmacology 2002; July

Rosebraugh CJ, Honig PK, Yasuda SU, Pezzullo JC, Woosley RL. Centers for Education and Research on Therapeutics report: Survey of medication errors education during undergraduate and graduate medical education in the United States. Clin Pharmacol Ther 2002;71:4-10

Yasuda SU, Zannikos P, Young AE, Fried KM, Wainer IW, Woosley RL. The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol 2002;53:519-525


2001

Desta Z, Soukhova N, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: Potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents and Chemother 2001;45:382-392

Desta Z, Soukhova N, Morocho AM, Flockhart DA. Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role in CYP3A. J Pharm Exp Ther 2001;298(2):508-520.

Katchman AN, Ebert SN, McCroary KA, Woosley RL. Methadone blocks HERG current in transfected HEK cells. Pharmacologist 2001;43:98

Kilborn MJ, Woosley RL. Registry for torsades de pointes with drug treatment exists. BMJ 2001;322:672

Remich SA, Kilborn MJ, Woosley RL. The role of internet-based registries in tandem with genetic screening for the study of drug-induced arrhythmias. Current Therapeutic Research 2001;62:787-795

Rodriguez I, Kilborn MJ, Liu XK, Pezzullo JC, Woosley RL. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001;285:1322-26.

Rosebraugh CJ, Flockhart DA, Yasuda SU, Woosley RL. Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient. J Clin Pharmacol 2001;41:224-27.

Rosebraugh CJ, Honig PK, Yasuda SU, Pezzullo JC, Flockhart DA, Woosley RL. Formal education about medication errors in internal medicine clerkships. JAMA 2001;286:1019-20.


2000

Benton Re, Sale M, Flockhart DA, Woosley RL. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 2000;674:413-418

Desta Z, Soukhouva N, Morocho A, Park J, Mahal SK, Flockhart DA. Stereoselective determination of cisapride, a prokinetic agent, in human plasma by chiral high-performance liquid chromatography with ultraviolet detection: application to pharmacokinetic study. J Chromatography B 2000;744:263-272

Flockhart DA, Desta Z, Mahal SK. Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions. Clin Pharmacokinet 2000;39:295-309.

Flockhart DA, Oesterheld JO. Cytochrome P450-mediated drug interactions. Child Adolesc Psychiatr Clin N Am. 2000; 9(1):43-76.

Wesche DL, Schuster BG, Wang WX, Woosley RL. Mechanism of cardiotoxicity of halofantrine. Clin Pharmacol Ther 2000;67:521-529

 
 

Arizona Center for Education and Research on Therapeutics
The Critical Path Institute

Tucson, Arizona and Rockville, Maryland

Funded in part by Agency for Healthcare Research and Quality grant 1 U18 HS10385-01

Disclaimer and Waiver
The information presented is intended solely for the purpose of providing general information about health related matters. It is not intended for any other purpose, including, but not limited to, medical or pharmaceutical advice and/or treatment, nor is it intended to substitute for the users' relationships with their own health care/pharmaceutical providers. To that extent, by continued use of this program, the user affirms the understanding of the purpose and releases The Critical Path Institute, The University of Arizona, State of Arizona and Arizona Board of Regents from any claims arising out of his/her use of the website.

Information Center For Consumers Arizona CERT Home For Professionals